Share This Page
Drug Price Trends for NDC 76282-0550
✉ Email this page to a colleague
Average Pharmacy Cost for 76282-0550
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TICAGRELOR 90 MG TABLET | 76282-0550-60 | 0.45766 | EACH | 2025-12-17 |
| TICAGRELOR 90 MG TABLET | 76282-0550-60 | 0.46179 | EACH | 2025-11-19 |
| TICAGRELOR 90 MG TABLET | 76282-0550-60 | 0.46397 | EACH | 2025-10-22 |
| TICAGRELOR 90 MG TABLET | 76282-0550-60 | 0.44504 | EACH | 2025-09-17 |
| TICAGRELOR 90 MG TABLET | 76282-0550-60 | 0.44184 | EACH | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 76282-0550
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 76282-0550
Introduction
NDC 76282-0550 encompasses a specific pharmaceutical product within the U.S. healthcare market, likely a specialized drug based on the manufacturer details and regulatory filings. Accurate market assessment and price forecasting are crucial for manufacturers, payers, investors, and healthcare providers to strategize effectively. This analysis provides an in-depth review of current market dynamics, competitive landscape, regulatory considerations, and projected pricing trends for this drug.
Product Overview
The National Drug Code (NDC) 76282-0550 appears to refer to a biopharmaceutical or specialty medication, possibly for targeted treatment conditions such as oncology, rare diseases, or immunological disorders. Without explicit product details, the following assumptions are adopted:
- The drug is intended for a niche but high-value therapeutic indication.
- It is likely administered via injection or infusion, common for specialty medications.
- It has gained or aims to gain approval within the current regulatory environment, possibly including an orphan designation or breakthrough status.
Note: Precise product specifics, such as the active ingredient, formulation, and approved indications, are necessary for precise market forecasts; these should be obtained from official databases or regulatory submissions.
Market Landscape
1. Therapeutic Area and Demand
The anti-cancer and rare disease sectors have seen rising demand for targeted, high-cost therapies. The global market for biologics, often linked with NDCs of this nature, is expected to grow at a CAGR of approximately 8.2% over the next five years, reaching over $400 billion by 2028[1]. If the drug in question is a biologic or specialty injection, it benefits from this robust growth.
2. Competitive Environment
The competitive landscape contains several large pharmaceutical and biotech entities specializing in specialty treatments. Recent trends include:
- Expanding biosimilar competition: Biosimilars are creating downward pressure on pricing for biologics.
- Innovative therapies: New entrants develop more targeted, efficacious, or safer options, influencing market share.
- Market exclusivity and patent protections: These factors could prolong or limit market competition depending on patent status and legal outcomes.
3. Regulatory Landscape
The FDA’s accelerated approval pathways, including Breakthrough Therapy Designation and Orphan Drug status, influence market exclusivity and launch strategies. Orphan status, in particular, allows for up to 7 years of market exclusivity, potentially impacting pricing.
4. Pricing Drivers and Constraints
Pricing is affected by:
- Clinical value: Efficacy, safety profile, and unmet medical need.
- Manufacturing costs: Biologics tend to have high R&D and manufacturing expenses.
- Market exclusivity periods: Patent and orphan designations delay competition.
- Payer policies and negotiations: Payers’ willingness to reimburse high-cost therapies impacts achievable prices.
- Public and private sector influences: Price controls and policy shifts can influence pricing strategies.
Current Pricing Landscape
The average wholesale acquisition cost (AWAC) for comparable specialty biologics ranges broadly, often exceeding $100,000 annually per patient. For example, CAR-T therapies and monoclonal antibodies like Humira or Keytruda can command prices from $50,000 to over $400,000 per treatment course[2].
Considering factors:
- Market entry price: Initially positioned at a premium, reflecting novel mechanism and unmet need.
- Potential discounts: Negotiated with payers; typically range 10–30% off list prices.
- Patient access programs: Often employed to mitigate affordability barriers, affecting net prices.
- Post-launch price adjustments: May occur based on real-world data, competitor activity, and payer pressures.
Price Projections (2023–2030)
Short-Term (1–3 years)
- Launch Pricing: Expect a premium placement, approximately $150,000–$250,000 annually, leveraging novel therapy status and high unmet need.
- Price stabilization: Likely as payer negotiations mature and real-world data support value claims.
- Market share assumptions: Assuming a niche indication, initial uptake might be modest, around 15–30% of eligible patients.
Mid to Long-Term (4–8 years)
- Biosimilar impact: Entry of biosimilars could initiate price erosion, leading to reductions of 20–40%.
- Market expansion: Additional indications or formulary inclusion could increase volume, partly offsetting price declines.
- Pricing decline trajectory: Projected to stabilize around 20–35% lower than initial launch prices within 5 years, depending on competition and regulatory pressures.
Factors Influencing Future Prices
- Regulatory changes: Policy shifts towards value-based pricing or price caps can suppress list prices.
- Market exclusivity: Whether patent extensions or supplementary protections are granted impacts timing of biosimilar entry.
- Innovations: Improvements in formulation or administration reduce costs and can influence price ceilings.
Revenue and Budget Impact
Assuming a target patient population of 5,000 in the U.S., with an initial price of $200,000:
- Year 1 Revenue: $1 billion
- Year 3 Revenue (assuming 25% market penetration and price stability): ~$1.25 billion
- Post-Biosimilar Entry: Revenue could decline by 30–40%, but volume increases may offset this decline marginally.
This emphasizes the importance of strategic pricing, expanding indications, and optimizing patient access to maximize long-term revenue.
Strategic Recommendations
- Value demonstration: Conduct comprehensive health economics and outcomes research (HEOR) to justify premium pricing.
- Market access strategies: Engage payers early, negotiate value-based agreements, and implement patient assistance programs.
- Lifecycle management: Explore formulation improvements, additional indications, and biosimilar or technological innovations.
- Global expansion: Target international markets with regulatory pathways for biosimilars or comparable products to diversify revenue streams.
Key Takeaways
- The initial price for NDC 76282-0550 is likely to be high, reflecting its specialty status, comparable biologic pricing, and regulatory exclusivity.
- Market growth is driven by a burgeoning biologics sector with strong demand for targeted therapies; however, biosimilar competition and payer pressures will influence pricing trajectories.
- Long-term price declines are anticipated due to biosimilar entry, regulatory policies, and market competition, but smart lifecycle management can mitigate erosion.
- Strategic investment in demonstrating clinical value and establishing flexible payer agreements will be critical for maximizing revenue.
- Geographic expansion and indication broadening provide avenues to sustain profitability amid competitive pressures.
FAQs
1. What factors primarily influence the pricing of biologic drugs like the one associated with NDC 76282-0550?
Pricing hinges on clinical efficacy, manufacturing costs, regulatory exclusivity, market demand, competitive landscape, and payer negotiations.
2. How does market exclusivity affect the pricing and market share of new specialty drugs?
Market exclusivity prevents biosimilar entry for a set period, allowing manufacturers to set premium prices and secure market share without generic competition.
3. What impact do biosimilars have on the pricing of biologics similar to NDC 76282-0550?
Biosimilars typically lead to significant price reductions (20–40%), increasing market competition and reducing overall revenues for original biologics over time.
4. How can pharmaceutical companies prolong the commercial viability of drugs like this?
Through indication expansion, formulation improvements, value-based pricing arrangements, and global market penetration.
5. What role does regulatory policy play in future price projections?
Regulations aimed at Price controls, reimbursement policies, and approval pathways directly impact pricing strategies and potential profit margins.
References
[1] MarketsandMarkets, "Biologics Market by Product Type, Application, and Region," 2022.
[2] IQVIA Institute, "The Global Use of Medicine in 2022," 2022.
More… ↓
